Schizophrenia
Pipeline by Development Stage
Drug Modality Breakdown
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.6yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
On Market (27)
Approved therapies currently available
Competitive Landscape
91 companies ranked by most advanced pipeline stage
+61 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 49 trials with date data
Clinical Trials (50)
Total enrollment: 5,347 patients across 50 trials
The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients
A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.
A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder
A Study to Evaluate the Effect of KarXT on Urological Safety
KarXT Concentrations in the Breast Milk and Plasma of Lactating Females
Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients
An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
C-Cog in Early Course Schizophrenia Study
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
Biomarkers in Clozapine-responding Schizophrenia
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Target Engagement and Response to Oxytocin
MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine
Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch
Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia
Association of Amisulpride Response in Schizophrenia With Brain Image
Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)
A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia
Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia
A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug
Once-Daily Asenapine for Schizophrenia
Pregablin for Anxiety-comorbidity in Patients With Schizophrenia
Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia
Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients
A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study
Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital
Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy
Different Safety Profile of Risperidone and Paliperidone Extended-release
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation
Efficacy and Safety of Paliperidone ER in First Episode Psychosis
Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia
Related Jobs in Neurology
Director, Clinical Quality Assurance
Director, Regulatory Affairs
Principal Scientist, Analytical Development – Drug Substance
Sr. Medical Director, Pharmacovigilance
Corporate Strategy Intern
Promotional Materials Review Committee Manager
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.